Presenting the results – not today, not tomorrow, but a statement that fuels a trading frenzy for Provectus Pharmaceutical Inc. (OTC:PVCT) one more time. Indeed, one of the few OTCBB companies out there that maintain such stability on the stock market. 
Gravitating around $1 per share. 52-week high – 1.32; 52-week low – 0.78 per share. A development-stage enterprise as the name suggests – a pharmaceutical company focused on destroying the deadliest cancers and on treating chronic immune-mediated diseases. Preparations on the way for Phase 3 trials. And, as mentioned, the company would present the Phase 2 clinical results for one of its products at two upcoming conferences. This is what the latest press release includes – results are to be presented at the conferences next Tuesday and next Saturday.
Now, if simply announcing the above could sparkle trading activity of more than 1.5 million shares changing hands, what would be the impact on the stock market right after the conferences? What is more, this company shares an interesting balance sheet. The last 10-Q, for example, covering a period with an end-date March 31st, 2011 includes the following data:
- $12 million in total current assets (cash mostly); [BANNER]
- $718k in total current liabilities;
- $91 million in accumulated deficit;
- $5 million in net loss;
So, on one hand, there is the ratio assets-liabilities, which brings a level of confidence to some extent. On the other hand, there is the rate of burning cash to fund the company activities – $5 million per quarter. Not exceptional for a pharmaceutical enterprise, still not to go overlooked. Besides, Phase 3 trials results are the ones to prove that long-term investors have made the right choice a long time ago. Trials, yet to commence. Trials which need funding and securing additional funding is not always to the immediate benefit of shareholders.
